Zymeworks Inc. is a biotechnology company that manages a portfolio of licensed healthcare assets and develops a pipeline of novel, multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases. The company operates through an asset and royalty aggregation strategy, generating cash flows from milestone payments and royalties while investing in internal research and development. Key products include Ziihera (zanidatamab-hrii), a bispecific antibody for HER2-positive biliary tract cancer, and pasritamig, a bispecific T cell engager for prostate cancer. Zymeworks utilizes proprietary technology platforms, including Azymetric, for multispecific antibody therapeutics and antibody-drug conjugates. The company partners with major pharmaceutical firms such as Jazz Pharmaceuticals, BeOne Medicines, Johnson & Johnson, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, and Merck to share development risks and secure royalty streams. Its operations span global markets, with regulatory approvals for Ziihera in the United States, China, Europe, and Canada.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage zymeworks.com
Sector Healthcare IR page ir.zymeworks.com
Tags
bispecific antibodies, antibody-drug conjugates, oncology, autoimmune disease, inflammation, royalty portfolio, protein engineering, t cell engagers, her2-positive cancer, prostate cancer, Ziihera, zanidatamab-hrii, pasritamig, JNJ-78278343, Azymetric, MSATs, ADCs, BeOne Medicines, Jazz Pharmaceuticals, Johnson & Johnson, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Merck
Press page zymeworks.com/news

Metrics

Valuation  
Market cap $ 1.776B
Market cap (USD) $ 1.776B
P/E 47.98
PEG —
P/BV 6.88
P/S 6.68
P/OCF -15.86
P/FCF -15.74
Dividend yield —
Turnover / mcap —
Returns  
ROE -26.7%
ROI -35.7%
ROIC -30.5%
Profit margin -76.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 131.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 112
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 105.965M 76.304M 76.012M 412.482M 26.68M 38.951M 29.544M 53.019M —
Net profit -81.13M -122.695M -118.674M 124.341M -211.843M -180.552M -145.437M -36.556M -10.406M
Free cash flow -34.526M -112.035M -120.777M 135.959M -204.855M -155.713M -88.175M 23.374M -1.796M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 26.33 14.64 10.39 7.86 16.39 47.26 45.46 14.68 7.6
Price performance 12m 0.8 0.41 0.32 -0.52 -0.65 0.04 2.1 0.93 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.65M 238,000 358,000 2.19M 15.3M 15.6M 33.4M 19.5M 55.8M 4.64M
↳ YoY growth -91.0% +50.4% +510.3% +599.9% +2.1% +113.9% -41.7% +186.6% -91.7%
↳ 5y CAGR +42.6% +168.8% +122.4% +91.2% -21.2%
Borrowings, current (USD) 4.42M 4.42M — — — — — — — —
Lease liabilities (USD) — 491,000 333,000 6.94M 8.66M 32.4M 28.1M 26.8M 18.5M 18.3M
Cash and deposits (USD) 16.4M 35.9M 42.2M 128M 242M 202M 401M 158M 66.1M 41.2M
Intangible assets (USD) 699,000 748,000 1.61M 6.06M 5.3M 3.84M 8.76M 7.66M 4.58M 1.35M
Right-of-use assets (USD) — — 3.22M 5.4M 5.43M 27M 22.9M 17.7M 16.7M 15.7M
Net debt (borrowings + leases - cash) (USD) -12M -31M — — — — — — — —
Cash flow detail
Operating cash flow (USD) -35.2M 219,000 24.2M -81.9M -151M -192M 144M -118M -110M -33M
Purchases of property, plant and equipment (USD) 4.43M 2.02M -803,000 -6.32M -4.31M -12.4M -8.15M -2.47M -1.99M -1.52M
Purchases of intangible assets (USD) 1.04M 1.11M -2.62M -7.56M -1.96M -881,000 -4.98M -1.6M -1.08M -831,000
Change in receivables (cash effect) (USD) 592,000 -2.41M -119,000 -1.83M -13.1M -266,000 -17.5M 13.9M -36.4M 51.2M
Change in payables (cash effect) (USD) 1.93M -358,000 3.68M 21.6M 7.62M 16.5M 26.5M -44.8M 14.3M -23.6M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -30.1M -41.7M
Income taxes paid (cash effect) (USD) — — — — — — -10M -165,000 -3.18M -1.35M
Share-based compensation (USD) 4.29M 3.43M 13.4M 49M 29.1M 10.8M 4.02M 8.1M 17.8M 28M
Operating cash flow before change in receivables (USD) -35.8M 2.63M 24.3M -80M -138M -192M 162M -132M -73.7M -84.2M
Free cash flow (OCF - PPE - intangibles) (USD) -40.7M -2.9M 20.8M -95.7M -158M -206M 131M -122M -113M -35.4M
Income detail
Research and development expense (USD) 36.8M 41.7M 56.7M 116M 169M 200M 209M 144M 135M 137M
↳ 5y CAGR +46.9% +40.2% +38.0% +20.4% +3.0% -4.1%
Total comprehensive income (USD) -33.8M -10.4M — — -181M -212M 124M -119M -123M -80.3M
Comprehensive income to owners (USD) -33.8M -10.4M — — -181M -212M 124M -119M -123M -80.3M
Reported Mar 2, 2020 Mar 6, 2019 May 2, 2019 Feb 24, 2021 Mar 7, 2023 Mar 7, 2023 Mar 5, 2025 Mar 5, 2025 Mar 5, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Zymeworks Announces $200 Million Share Repurchase Authorization Bull 3 Bear 0 Capital return

•Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR)

•Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time

Vancouver, British Columbia (November 16, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share.

Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock.

•2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 million (previously between $114 million and $128 million)

•Ziihera® first-line advanced gastroesophageal adenocarcinoma (GEA) approval by the U.S. FDA expands royalty opportunity and provided a $250 million U.S. approval milestone

•Collaboration agreement with Roche, once Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 clearance obtained, will provide a pathway for ZW209 value creation from capital-efficient R&D while preserving meaningful long-term economic participation

•The Company plans to host an R&D Day in New York on February 11th, 2027

Vancouver, British Columbia (November 9, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2026 and provided a summary of recent business highlights.

We are pleased to present preclinical data on our novel IL-7 immunocytokine in a poster presentation at the annual Society for Immunotherapy of Cancer (SITC) Conference, taking place November 4-8 in Pheonix, Arizona.

Presentation Highlights

Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
Abstract Number: 810

PD-1 blockade is the standard of care across multiple cancer indications, but benefit is not always durable, and many patients do not respond. By simultaneously neutralizing tumor angiogenesis, PD-1 x VEGF bispecific antibodies offer an opportunity to increase clinical responses, but benefit to patients could be further enhanced by increasing the durability of anti-tumor immune response.

In this poster, we describe a PD-1 x VEGF multispecific antibody carrying an engineered IL-7 that is attenuated and masked so that IL-7 signals mainly on PD-1-positive T cells, with minimal activity on bystander T cells. The product candidate builds on our protein engineering and immunology expertise, including our experience engineering attenuated, conditionally active, targeted cytokines, and on an AI-driven, high-throughput multispecific workflow that lets us screen and refine designs rapidly. The transition from PD-1 bispecific antibodies to trispecific antibodies aims to address the clinical limitations of current checkpoint approaches.

Key Highlights:

  • Combining a selected IL-7 mutation with masking strategies in the IL-7mut x PD-1 x VEGF multispecific provides approximately 200- to 1000-fold selectivity for PD-1+ T cells
  • The VEGF-binding domain acts as a mask for IL-7 in addition to full-strength VEGF blockade equipotent to clinical benchmarks
  • PD-1 blocking domain provides sustained, complete PD-1 inhibition equivalent to clinical antibody benchmark
  • Format-dependent properties allow complexing with VEGF for enhanced PD-1 blockade and IL-7 potency
  • IL-7mut x PD-1 x VEGF enhances T cell survival, function and fitness, and can restore function to exhausted T cells in patient tumor samples
  • An automated, AI-driven workflow using Azymetric™ solutions for proper chain pairing enabled rapid development of 3- and 4-chain IL-7 immunocytokine constructs

The poster is available to conference attendees as a virtual e-poster on the SITC website, as well as on Zymeworks’ website at https://www.zymeworks.com/publications/.

Linkedin-in

©2026, Zymeworks Inc.

Manage consent

Prompts

Zymeworks Inc. (ticker ZYME), listed in United States.

Company History

Date Change Detail
Aug 11, 2026 Acquired Acquired Theravance Biopharma, Inc. (CIK 1583107). Its filings from before the deal are on its own company page, not shown here.
Jul 15, 2022 Renamed ZYMEWORKS INC. → ZYMEWORKS DELAWARE INC.

ETFs Holding Zymeworks Inc.

ETF Weight in ETF Shares Market value As of
CANC 1.54% 110,609 $ 3.253M Aug 31, 2026
MMSC 0.28% 5,361 $ 141.798K Nov 16, 2026
FSCC 0.16% 20,340 $ 598.199K Aug 31, 2026
PSC 0.09% 80,480 $ 2.104M Jun 30, 2026
FSML 0.08% 3,811 $ 99.62K Jun 30, 2026
FSEG 0.08% 168 $ 4,391.52 Jun 30, 2026
RESM 0.06% 82 $ 2,143.48 Jun 30, 2026
VFMO 0.04% 26,119 $ 768.16K Aug 31, 2026
FESM 0.04% 78,711 $ 2.058M Jun 30, 2026
DFAS 0.03% 316,341 $ 8.374M Nov 12, 2026
MSSM 0.01% 3,438 $ 101.112K Aug 31, 2026
DFAC 0.00% 87,456 $ 2.315M Nov 12, 2026
DFUS 0.00% 11,857 $ 313.855K Nov 12, 2026
DCOR 0.00% 1,744 $ 46.164K Nov 12, 2026
DXUV 0.00% 132 $ 3,494.04 Nov 12, 2026